UNSPSC 51281638: Betamicin sulfate

This classification denotes the sulfate form of an aminoglycoside antibiotic with the molecular structure C19H38N4O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 67W9DGG4C7 chemically known as d-streptamine, o-6-amino-6-deoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6))-2-deoxy-, but more commonly known as betamicin, which bears US NIH Compound Identifier 37569.

UNSPSC 51281638 Betamicin sulfate is a Commodity code for a specific pharmaceutical active ingredient, but the recent state and local solicitations tagged under it do not reflect procurement of betamicin sulfate itself. The Illinois Department of Public Health's completed MMCAP Infuse consortium piggyback contract, awarded to Chartwell Rx LLC on August 28, 2026, supplies Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets over a three-year term for $2,999,999.11 total. Seminole County, Florida's competitive bid for naloxone and safe drug deactivation systems, posted June 30, 2026, sought 1,900 units of naloxone and 800 deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford. Neither opportunity directly involves betamicin sulfate procurement. State and local health departments and county public health agencies appear to be the primary issuing bodies under this code, but the recent opportunities show a mismatch between the code's pharmaceutical specification and the actual products being sourced.

The code shows minimal relevant recent activity aligned with betamicin sulfate itself. Geographic representation in the available records spans Illinois and Florida, with procurement flowing through state health department and county health authority channels. The Illinois award was completed through an IFB process via a cooperative purchasing vehicle (MMCAP Infuse consortium), while Seminole County used a competitive IFB with a response deadline of July 26, 2023—an outdated date that suggests either a data lag or an archived posting. Neither opportunity explicitly names betamicin sulfate as a line item, indicating the code may be misapplied to these records or that pharmaceutical commodity coding practices differ across jurisdictions. Pursuit of this code warrants verification with state and local health procurement offices to determine whether betamicin sulfate is actively sourced as a standalone pharmaceutical product or whether it is bundled into broader pharmaceutical supply agreements coded elsewhere.